Get the Stockscreener App
0.0007
33.64%
-0.0596
Paxmedica Inc stock is traded at $0.0007, with a volume of 710.
It is down -33.64% in the last 24 hours and down -57.01% over the past month.
See More
Previous Close:
$0.0603
Open:
$0.0005
24h Volume:
710
Relative Volume:
66.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-17.66M
P/E Ratio:
-0.000102
EPS:
-6.8879
Net Cash Flow:
$-9.32M
1W Performance:
-33.64%
1M Performance:
-57.01%
6M Performance:
-93.93%
1Y Performance:
-85.81%
1-Day Range:
$0.0005
$0.0007
1-Week Range:
$0.0005
$0.0007
52-Week Range:
$0.0005
$0.0007
Paxmedica Inc Stock (PXMD) Company Profile
Compare PXMD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PXMD
Paxmedica Inc
|
0.0007 | 0 | 0 | -17.66M | -9.32M | -6.8879 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.29 | 116.01B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.58 | 80.33B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
729.07 | 44.42B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.98 | 42.53B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
298.77 | 33.32B | 5.36B | 287.73M | 924.18M | 2.5229 |
Paxmedica Inc Stock (PXMD) Latest News
Strategic Execution in Focus for Paxmedica Investors - AD HOC NEWS
ProMetic Life Sciences (OTCMKTS:PFSCF) & PaxMedica (NASDAQ:PXMD) Financial Contrast - Defense World
Comparing PaxMedica (NASDAQ:PXMD) & ProMetic Life Sciences (OTCMKTS:PFSCF) - Defense World
Paxmedica’s PAX-101 Under the Microscope: Pipeline Progress and FDA Milestones - AD HOC NEWS
MorphoSys (NASDAQ:MOR) vs. PaxMedica (NASDAQ:PXMD) Head to Head Comparison - Defense World
Autism Spectrum Disorder Market to Reach USD 4.07 Billion - GlobeNewswire
PXMD Stock Institutional Owners - Quiver Quantitative
Plus Therapeutics Regains Compliance With Two Nasdaq Listing Rules - marketscreener.com
Delisting of Securities from The Nasdaq Stock Market - The Manila Times
PaxMedica Renames to Kuvatris, Cancels Shares - TipRanks
PaxMedica announces board resignations amid transition - Investing.com
PaxMedica Holds Important FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data - ACCESS Newswire
PaxMedica Announces Resignation of Key Executives - TipRanks
PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection - ACCESS Newswire
PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions - ACCESS Newswire
Craft Capital Management Announces Pricing of Initial Public Offering for PaxMedica, Inc. - ACCESS Newswire
PaxMedica, Inc. (PXMD) Stock Price, News, Quote & History - Yahoo
PaxMedica Secures Groundbreaking China Patent for Autism Treatment Breakthrough After 100 Years - Stock Titan
Autism Spectrum Disorder Therapeutics Market size is set to grow by USD 766.1 million from 2024-2028, Increasing prevalence of asd to boost the market growth, Technavio - PR Newswire
PaxMedica (PXMD) Stock Trends and Sentiment 2025 - MarketBeat
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Dedicated to Ensuring Access to Life-Saving Treatments - FinancialContent
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101 - Yahoo Finance
Cardio Diagnostics Holdings, Inc. (CDIO) stock price, news, quote and history - Yahoo! Finance Singapore
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy - Yahoo Finance
PXMD Stock Price and Chart — OTC:PXMD - TradingView
PaxMedica Inc. (NASDAQ: PXMD) Announces PAX-101 Batch Completion for NDA Application to FDA - FinancialContent
PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast - GlobeNewswire
As Autism Cases Rise, Biopharma Springs Into Action - BioSpace
Malawi’s Health Ministry Seeks Emergency Access to PaxMedica’s IV Suramin - NAVLIN DAILY
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness - Yahoo Finance
Why Is PaxMedica (PXMD) Stock Up 93% Today? - InvestorPlace
PaxMedica Achieves Key Milestone in the Development of - GlobeNewswire
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments - GlobeNewswire
PaxMedica (NASDAQ: PXMD) Dedicated to Enhancing Quality of Life for Individuals with ASD - The Globe and Mail
Ocean Biomedical, Inc. (OCEA) options chain - Yahoo! Finance Singapore
HC Wainwright & Co. Initiates Coverage of PaxMedica (PXMD) with Buy Recommendation - Nasdaq
PaxMedica (NASDAQ: PXMD) Closes on Public Offering Reaching Estimated $7M - The Globe and Mail
PaxMedica prices stock and warrant offering at $1.30 per unit - Investing.com UK
PaxMedica, Inc. (PXMD) latest stock news and headlines - Yahoo Finance UK
PaxMedica News of FDA Type-B Meeting Shared in Audio Broadcast - Yahoo Finance
Why Is PaxMedica (PXMD) Stock Down 40% Today? - TradingView — Track All Markets
Virax Biolabs Group Limited (VRAX) stock price, news, quote and history - Yahoo! Finance Singapore
What LIFW, PXMD, and NVOS have in common - StocksToTrade
PaxMedica Surges After Publication Of Statistically Significant Data From Its Autism Spectrum Study - Nasdaq
PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV) - FinancialContent
PaxMedica buys research assets to support PAX-101 FDA application (PXMD) - Seeking Alpha
PaxMedica Announces 1-for-17 Reverse Stock Split - GlobeNewswire
PaxMedica (NASDAQ: PXMD) Reports on Low-Dose Suramin for ASD Research - Digital Journal
PaxMedica stock soars 110% on FDA update for lead drug PAX-101 (PXMD) - Seeking Alpha
The Bell2Bell Podcast featuring Howard Weisman, CEO and Buzz Woods of PaxMedica, Inc. (Nasdaq: PXMD) - Yahoo Finance
PaxMedica Announces Gold Sponsorship of The BRAIN Foundation's Synchrony Symposia 2023 - Yahoo Finance
Paxmedica Inc Stock (PXMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
0.06%
Cap:
|
Volume (24h):